Telix Pharmaceuticals (TLX) Short term Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Short term Debt data on file, last reported at $13.1 million in Q4 2025.

• Short term Debt for Q4 2025 came in at $13.1 million, up 5.57% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.1 million (up 5.57% YoY), and the FY2025 annual result was $13.1 million, up 11.45% from the prior year.
• Short term Debt grew to $13.1 million in Q4 2025 per TLX's latest filing, from $12.4 million in the prior quarter.
• Over five years, Short term Debt peaked at $13.1 million in Q4 2025 and troughed at $627554.8 in Q4 2023.
• A 3-year average of $8.7 million and a median of $12.4 million in 2024 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2024 and 2025: Short term Debt jumped 1878.89% in 2024, then advanced 5.57% in 2025.
• A 3-year view of Short term Debt shows it stood at $627554.8 in 2023, then jumped by 1878.89% to $12.4 million in 2024, then climbed by 5.57% to $13.1 million in 2025.
• Business Quant data shows TLX's Short term Debt at $13.1 million in Q4 2025, $12.4 million in Q4 2024, and $627554.8 in Q4 2023.